A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
← catalyst calendarNCT07652736 · readout in 453 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
440estimated
Sites
1
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-05 | actual | When the study began enrolling |
| Primary completion | 2027-11-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-17 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Non-Small Cell Lung Cancer
- Extensive-Stage Small Cell Lung Cancer
Intervention
- Drug: Tislelizumab
Primary outcomes
what the primary-completion date above is the date OFTime from Diagnosis to First Dose
measured From date of first tislelizumab administration up to 30 months
Duration of Treatment
measured From date of first tislelizumab administration up to 30 months
Number of Participants with Dose Modifications
measured From date of first tislelizumab administration up to 30 months
Number of Participants with Treatment Discontinuation
measured From date of first tislelizumab administration up to 30 months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed